Lifestyle change is the first treatment for prediabetes, but medication can help when blood sugar continues to rise or risk is very high. The most evidence-supported options are metformin, acarbose, GLP-1 receptor agonists (such as semaglutide), and orlistat. None are FDA-approved specifically for prediabetes — all are prescribed off-label based on clinical guidelines.
Why Lifestyle Comes First
The Diabetes Prevention Program (DPP), the largest prediabetes trial in history, compared lifestyle change to metformin in over 3,000 adults with prediabetes:
- Lifestyle change (7% weight loss, 150 minutes of weekly exercise): reduced progression to type 2 diabetes by 58%.
- Metformin: reduced progression by 31%.
Lifestyle outperformed medication. That is why every guideline — ADA, CDC, USPSTF — recommends an intensive lifestyle program first. The CDC’s National Diabetes Prevention Program offers structured year-long classes covered by Medicare and many private insurers.
That said, lifestyle change is hard to sustain, and some people have such high risk that medication adds meaningful benefit. The decision is individual.
When Medication May Be Considered
The American Diabetes Association suggests considering medication for prediabetes when one or more of the following apply:
- A1C 5.7 – 6.4% with a BMI of 35 or higher (especially under age 60)
- History of gestational diabetes
- A1C continues to rise despite lifestyle change
- Strong family history of type 2 diabetes
- Other significant cardiovascular risk factors
Quick Comparison: Prediabetes Medication Options
| Medication | Class | Mechanism | Diabetes Risk Reduction | Common Side Effects |
|---|---|---|---|---|
| Metformin | Biguanide | Reduces liver glucose; improves insulin sensitivity | ~31% | Diarrhea, nausea, B12 deficiency |
| Acarbose | Alpha-glucosidase inhibitor | Slows carb absorption in gut | ~25 – 30% | Gas, bloating, diarrhea |
| Semaglutide / liraglutide | GLP-1 agonist | Slows gastric emptying; reduces appetite; lowers glucose | ~60 – 80% (via weight loss) | Nausea, vomiting, possible pancreatitis |
| Orlistat | Lipase inhibitor | Blocks ~30% of dietary fat absorption | ~37% (XENDOS trial) | Oily stool, GI urgency, fat-soluble vitamin loss |
| Pioglitazone | Thiazolidinedione | Improves insulin sensitivity | ~70% (ACT NOW trial) | Weight gain, edema, fracture risk |
Metformin: The Most Studied Option
Metformin is the most widely prescribed off-label medication for prediabetes. It has been used since the 1950s, costs pennies a pill, and has a strong safety record.
How It Works
Metformin reduces glucose production by the liver, improves insulin sensitivity in muscle and fat, and slightly reduces intestinal glucose absorption. It does not cause hypoglycemia when used alone.
Typical Dosing
Usually started at 500 mg once daily with a meal, increased over weeks to 500 – 1,000 mg twice daily. Extended-release forms reduce GI side effects.
Side Effects
- Diarrhea, nausea, abdominal discomfort (most common; usually improves)
- Vitamin B12 deficiency with long-term use (annual B12 check recommended)
- Rarely, lactic acidosis (in advanced kidney or liver disease)
Who Should Avoid It
Severe kidney impairment (eGFR under 30), unstable heart failure, or active liver disease.
Read more in our dedicated guide on metformin for prediabetes.
Acarbose
Acarbose is an alpha-glucosidase inhibitor that slows the breakdown of complex carbohydrates in the small intestine, blunting post-meal glucose spikes. The STOP-NIDDM trial showed about a 25% reduction in progression to type 2 diabetes.
Typical Dosing
25 mg with the first bite of each meal, titrated up to 50 – 100 mg per meal.
Side Effects
- Gas, bloating, and diarrhea — very common, especially early on
- Liver enzyme elevations at high doses
Acarbose is most often used in patients who have prominent post-meal glucose elevations.
GLP-1 Receptor Agonists (Semaglutide, Liraglutide)
GLP-1 agonists are injectable medications originally developed for type 2 diabetes and now widely used for weight management. Brand names include Ozempic and Wegovy (semaglutide), Saxenda and Victoza (liraglutide), and Zepbound and Mounjaro (tirzepatide, a GLP-1/GIP dual agonist).
How They Work
- Slow gastric emptying (you feel full longer)
- Reduce appetite via brain receptors
- Increase insulin secretion in response to meals
- Decrease glucagon (a glucose-raising hormone)
The result is significant weight loss — averaging 10 to 20% of body weight in clinical trials. Because weight loss is the most powerful lever in prediabetes reversal, this often normalizes glucose.
Approval Status
Wegovy (semaglutide 2.4 mg weekly) is FDA-approved for chronic weight management in adults with BMI ≥30, or BMI ≥27 with weight-related conditions. Many people with prediabetes meet these criteria. Use specifically for prediabetes is off-label.
Side Effects
- Nausea, vomiting, diarrhea (most common)
- Constipation
- Gallbladder problems
- Rarely, pancreatitis
- Boxed warning regarding thyroid C-cell tumors based on rodent studies
Considerations
Cost (often $900 – $1,300/month without insurance), supply shortages, and the question of long-term use are all factors. Glucose and weight tend to rebound after stopping.
Orlistat
Orlistat (Xenical prescription, Alli over-the-counter) blocks about 30% of dietary fat absorption. The XENDOS trial in obese adults with impaired glucose tolerance showed a 37% reduction in progression to type 2 diabetes over 4 years.
Side Effects
- Oily, loose, and frequent stools (especially with high-fat meals)
- Fat-soluble vitamin deficiencies (take a multivitamin 2 hours apart from doses)
- Rarely, severe liver injury
Pioglitazone
A thiazolidinedione that improves insulin sensitivity. The ACT NOW trial showed a 72% reduction in progression to type 2 diabetes in people with impaired glucose tolerance — the largest effect of any medication studied. However, side effects (weight gain, fluid retention, increased fracture risk, possible bladder cancer association) limit its use, and it is rarely chosen for prediabetes.
Other Approaches
Vitamin D and Other Supplements
The D2d trial found vitamin D 4,000 IU daily did not significantly reduce progression to type 2 diabetes overall, though some sub-analyses suggested benefit. Routine high-dose supplementation is not recommended; correcting documented deficiency is reasonable.
Bariatric Surgery
For people with severe obesity (BMI ≥40, or ≥35 with complications), bariatric surgery often resolves prediabetes and dramatically reduces diabetes risk. It is not first-line but may be discussed if other strategies fail.
Choosing the Right Medication
The decision depends on:
- Your A1C and how fast it’s rising
- BMI and weight goals
- Other health conditions (kidney function, heart disease, history of pancreatitis)
- Insurance coverage and cost
- Tolerance for side effects (oral vs. injection, GI effects)
- Pregnancy plans (most prediabetes drugs aren’t used in pregnancy)
For broader treatment context, see our medication for prediabetes overview.
How to Make the Most of Medication
- Continue lifestyle change — medication amplifies, doesn’t replace, the gains.
- Track A1C every 3 to 6 months.
- Monitor for side effects and follow up with your prescriber.
- Re-evaluate annually — many people can taper off medication after sustained weight loss.
- Get B12 levels checked if on metformin long-term.
What to Discuss with Your Doctor
- Your A1C trend over the past year
- Your BMI, blood pressure, and cholesterol
- Family history of diabetes and cardiovascular disease
- Whether you’ve tried structured lifestyle programs
- Insurance coverage for medications and DPP programs
- Side effects you’re most concerned about
The Bottom Line
No medication is FDA-approved specifically for prediabetes, but several — metformin, acarbose, GLP-1 receptor agonists, and orlistat — have strong evidence for reducing the risk of progression to type 2 diabetes. Lifestyle change remains the foundation of treatment; medication is added when risk is high or when diet, exercise, and weight loss alone aren’t enough. Talk with your doctor about which option, if any, fits your individual risk and goals.
